Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Danaher Corporation's third-quarter 2025 earnings showcased a balanced performance underpinned by solid demand in certain sectors, yet offset by ongoing challenges in others.</li><li>The company reported total sales of $6.1 billion, achieving a core revenue growth of 3%.</li><li>The quarter reflected Danaher’s resilience amid varied market conditions, leveraging its strong execution capabilities and strategic investments in innovation.</li></ul>

Danaher Corporation's third-quarter 2025 earnings showcased a balanced performance underpinned by solid demand in certain sectors, yet offset by ongoing challenges in others.The company reported total sales of $6.1 billion, achieving a core revenue growth of 3%.The quarter reflected Danaher’s resilience amid varied market conditions, leveraging its strong execution capabilities and strategic investments in innovation.

Danaher Corporation Is Powering Ahead With Explosive Bioprocessing Growth; But These Are The 4 Biggest Challenges Ahead!

Smartkarma AI, Smartkarma

αSK

Smartkarma AI

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
  <li>Danaher's core strength lies in its <a href="https://smartkarma.com/entities/danaher-corp-b5895b7c-d298-4432-826a-a33c4fda4dcf">Danaher </a>Business System (DBS), a deeply ingrained culture of continuous improvement that drives operational excellence and supports a disciplined M&amp;A strategy.</li>
  <li>The company is strategically positioned in attractive, high-growth end markets, including life sciences, diagnostics, and biotechnology, benefiting from long-term secular trends like personalized medicine and increased healthcare spending.</li>
  <li>Following a period of revenue normalization post-COVID, <a href="https://smartkarma.com/entities/danaher-corp-b5895b7c-d298-4432-826a-a33c4fda4dcf">Danaher </a>is poised for a return to growth, though it faces near-term headwinds from cautious customer spending, particularly in biopharma, and economic challenges in China.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Danaher's core strength lies in its Danaher Business System (DBS), a deeply ingrained culture of continuous improvement that drives operational excellence and supports a disciplined M&amp;A strategy.
  The company is strategically positioned in attractive, high-growth end markets, including life sciences, diagnostics, and biotechnology, benefiting from long-term secular trends like personalized medicine and increased healthcare spending.
  Following a period of revenue normalization post-COVID, Danaher is poised for a return to growth, though it faces near-term headwinds from cautious customer spending, particularly in biopharma, and economic challenges in China.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

<ul><li>Danaher Corporation's second-quarter 2025 results provided a comprehensive view of their financial performance, strategic initiatives, and market positioning.</li><li>The quarter was marked by notable achievements and some challenges, set within a complex macroeconomic environment.</li><li>From a financial perspective, Danaher reported sales of $5.9 billion, with core revenue growth of 1.5% year-overyear.</li></ul>

Danaher Corporation's second-quarter 2025 results provided a comprehensive view of their financial performance, strategic initiatives, and market positioning.The quarter was marked by notable achievements and some challenges, set within a complex macroeconomic environment.From a financial perspective, Danaher reported sales of $5.9 billion, with core revenue growth of 1.5% year-overyear.

Danaher Bets Big on Bioprocessing—Will Resilient Demand Outpace Market Headwinds?

<ul><li>Danaher Corporation reported its first quarter of 2025 financial results, surpassing expectations in revenue, earnings, and cash flow.</li><li>The company benefited from robust performance in bioprocessing and a spike in respiratory demand at its subsidiary, Cepheid.</li><li>Utilization of the Danaher Business System (DBS) enabled the company to drive innovation, market share gains, and efficiency.</li></ul>

Danaher Corporation reported its first quarter of 2025 financial results, surpassing expectations in revenue, earnings, and cash flow.The company benefited from robust performance in bioprocessing and a spike in respiratory demand at its subsidiary, Cepheid.Utilization of the Danaher Business System (DBS) enabled the company to drive innovation, market share gains, and efficiency.

Danaher Corporation: Navigating Market Volatility to Protect Its Market Position!

<ul><li>Danaher Corporation concluded 2024 with notable performance improvements across its business segments, emphasizing particularly encouraging results from its bioprocessing and Life Sciences instruments sectors.</li><li>The company's disciplined execution enabled solid cash flow generation and operating profit margin expansion.</li><li>Total sales for the year reached $23.9 billion, although core revenue saw a slight decline of 1.5%.</li></ul>

Danaher Corporation concluded 2024 with notable performance improvements across its business segments, emphasizing particularly encouraging results from its bioprocessing and Life Sciences instruments sectors.The company's disciplined execution enabled solid cash flow generation and operating profit margin expansion.Total sales for the year reached $23.9 billion, although core revenue saw a slight decline of 1.5%.

Danaher Corporation: An Insight Into Its Cepheid's Global Installed Base & Innovation! - Major Drivers

United States

Danaher Corporation designs, manufactures and markets professional, medical, industrial and commercial products and services in the sectors of test and measurement, environmental, life sciences, dental, and industrial technologies.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Danaher Corp (DHR US)

Danaher Corporation Is Powering Ahead With Explosive Bioprocessing Growth; But These Are The 4 Biggest Challenges Ahead!

Danaher Corporation's third-quarter 2025 earnings showcased a balanced performance underpinned by solid demand in certain sectors, yet offset by...

Baptista Research

Primer: Danaher (DHR UN) - Sep 2025

Danaher's core strength lies in its Danaher Business System (DBS), a deeply ingrained culture of continuous improvement that drives operational...

αSK

Danaher Bets Big on Bioprocessing—Will Resilient Demand Outpace Market Headwinds?

Danaher Corporation's second-quarter 2025 results provided a comprehensive view of their financial performance, strategic initiatives, and market...

Baptista Research

Danaher Corporation: Navigating Market Volatility to Protect Its Market Position!

Danaher Corporation reported its first quarter of 2025 financial results, surpassing expectations in revenue, earnings, and cash flow. The company...

Baptista Research

Danaher Corporation: An Insight Into Its Cepheid's Global Installed Base & Innovation! - Major Drivers

Danaher Corporation concluded 2024 with notable performance improvements across its business segments, emphasizing particularly encouraging...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)